deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT02288195

CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients

Phase III Study of Neoadjuvant Chemotherapy With Capecitabine and Oxaliplatin Versus Chemoradiation for Locally Advanced Rectal Cancer Patients

Sponsor: Affiliated Cancer Hospital of Shantou University Medical College

Conditions Rectal Neoplasms
Interventions Oxaliplatin Radiation capecitabine
Updated 13 times since 2017 Last updated: May 10, 2023 Started: Aug 13, 2014 Primary completion: Mar 17, 2021 Completion: Mar 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02288195, this PHASE3 trial focuses on Rectal Neoplasms and remains ongoing. Sponsored by Affiliated Cancer Hospital of Shantou University Medical College, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Nov 2019 · 17 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Jun 2025 · 5 months · monthly snapshot~Jun 2025 – present · 15 months · monthly snapshot

Change History

13 versions recorded

  1. Jun 2025 — Present [monthly]

    Unknown PHASE3

    Status: Active Not Recruiting → Unknown

  2. Jan 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 8 earlier versions

  1. Apr 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  6. Nov 2019 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Jun 2018 — Nov 2019 [monthly]

    Recruiting PHASE3

  8. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Affiliated Cancer Hospital of Shantou University Medical College
  • Cancer Hospital of Guangxi Medical University
  • First Affiliated Hospital of Chongqing Medical University
  • First Affiliated Hospital of Kunming Medical University
  • Fujian Cancer Hospital
  • Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Guangdong Provincial People's Hospital
  • Henan Cancer Hospital
  • Hubei Cancer Hospital
  • Jiangmen Central Hospital
  • Liaoning Cancer Hospital & Institute
  • Longyan City First Hospital
  • Meizhou People's Hospital
  • Shantou Central Hospital
  • Shengjing Hospital
  • Sun Yat-sen University
  • The First Affiliated Hospital of Guangzhou Medical University
  • The First Affiliated Hospital with Nanjing Medical University
  • The Third Affiliated Hospital of Kunming Medical College.
  • West China Hospital
  • Zhejiang Cancer Hospital
Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations